Obexelimab Completed Phase 2 Trials for Systemic Lupus Erythematosus Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02725515
A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus